ObjectiveHIV-associated neurocognitive disorder (HAND) occurs in a significant percentage of HIV-infected (HIV+) adults. Increased intraindividual variability (IIV) in cognitive function may be an early marker of emerging neurocognitive disorder, which suggests that IIV may be a sensitive measure of neurologic compromise in HIV. In the current study, we hypothesize that increased IIV may predict impending morbidity, including future cognitive decline and death.MethodIn 708 HIV+ participants followed longitudinally for up to 14 years, we assessed the role of dispersion in forecasting death and cognitive decline. Incident neurocognitive impairment was predicted in a mixed-effects ordinal logistic regression model using age, gender, baseline m...
ObjectiveNeurocognitive performance among older persons, including those living with HIV (people liv...
Background: The optimum method of defining cognitive impairment in virally suppressed people living ...
We followed a cohort of 223 intravenous drug users (99 HIV and 124 HIV+) for up to 3.5 years, examin...
The primary aim of the current study was to investigate the role neurocognitive dispersion, a form o...
Background: The longitudinal rate and profile of cognitive decline in persons with stable, treated, ...
BACKGROUND: The longitudinal rate and profile of cognitive decline in persons with stable, treated, ...
Despite the widespread use of combination antiretroviral therapy (cART), HIV-associated neurocogniti...
ObjectiveWhile HIV-associated neurocognitive disorders (HAND) remain prevalent despite combination a...
ObjectivesRecent studies suggest that intraindividual variability (IIV) of neuropsychological perfor...
BackgroundHuman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) can show var...
Neurocognitive dysfunction is a prevalent and disabling consequence of living with Human Immunodefic...
Cognitive efficiency decreases with age, and advancing age is the leading risk factor for most neuro...
ObjectivesWhile cognitive impairment is frequently reported in HIV‐positive individuals and has hist...
ObjectiveThe presentation of cognitive impairments in HIV-infected individuals has transformed since...
BackgroundAlthough combination antiretroviral therapy reduced the prevalence of HIV-associated demen...
ObjectiveNeurocognitive performance among older persons, including those living with HIV (people liv...
Background: The optimum method of defining cognitive impairment in virally suppressed people living ...
We followed a cohort of 223 intravenous drug users (99 HIV and 124 HIV+) for up to 3.5 years, examin...
The primary aim of the current study was to investigate the role neurocognitive dispersion, a form o...
Background: The longitudinal rate and profile of cognitive decline in persons with stable, treated, ...
BACKGROUND: The longitudinal rate and profile of cognitive decline in persons with stable, treated, ...
Despite the widespread use of combination antiretroviral therapy (cART), HIV-associated neurocogniti...
ObjectiveWhile HIV-associated neurocognitive disorders (HAND) remain prevalent despite combination a...
ObjectivesRecent studies suggest that intraindividual variability (IIV) of neuropsychological perfor...
BackgroundHuman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) can show var...
Neurocognitive dysfunction is a prevalent and disabling consequence of living with Human Immunodefic...
Cognitive efficiency decreases with age, and advancing age is the leading risk factor for most neuro...
ObjectivesWhile cognitive impairment is frequently reported in HIV‐positive individuals and has hist...
ObjectiveThe presentation of cognitive impairments in HIV-infected individuals has transformed since...
BackgroundAlthough combination antiretroviral therapy reduced the prevalence of HIV-associated demen...
ObjectiveNeurocognitive performance among older persons, including those living with HIV (people liv...
Background: The optimum method of defining cognitive impairment in virally suppressed people living ...
We followed a cohort of 223 intravenous drug users (99 HIV and 124 HIV+) for up to 3.5 years, examin...